$CBDL CBD Life Sciences Inc. (CBDL) Secures Landmark Agreement with Bronx Powerhouse Dispensary Smoking Scholars
https://www.accessnewswire.com/newsroom/en/he...ow-1077348
With New York dispensaries projected to surpass $4.4 billion in annual sales by 2027, CBDL secures a transformative partnership poised to generate multi-million-dollar revenues and accelerate nationwide expansion.
SCOTTSDALE, AZ / ACCESS Newswire / September 30, 2025 / CBD Life Sciences Inc. (OTC:CBDL), through its operating subsidiary CBD Vault, today announced a game-changing client acquisition with Smoking Scholars, a premier dispensary located at 784 Allerton Ave in the Bronx, New York. This strategic agreement, finalized following CBDL's successful showcase at the NECANN New Jersey Conference, positions the Company to capture a powerful share of the booming New York cannabis and CBD marketplace.
Smoking Scholars is a multi-million-dollar enterprise with an elite client roster stretching across the United States. Their decision to bring CBD Vault into their packed product catalog is a resounding endorsement of CBDL's premium formulations and an entry point into one of the most competitive and rewarding markets in the nation.
Under the agreement, Smoking Scholars has placed a significant initial order featuring:
CBD Pain Relief Cream
CBD Massage Oil
Full Spectrum Gummies
CBD Infused Tea
Reishi Mushroom Face Cream
This order alone has the potential to generate hundreds of thousands in revenue within the next 12 months, with repeat orders expected as consumer demand for CBD wellness products accelerates. Importantly, this is just one of many dispensaries CBDL is securing as part of its rapid nationwide expansion.
Tapping Into One of America's Fastest-Growing Markets
New York's cannabis industry is undergoing explosive growth, with annual dispensary sales projected to exceed $4.4 billion by 2027. Consumer spending in the state is surging across both recreational and wellness categories, creating unparalleled opportunities for innovative brands like CBD Vault.
"Securing a powerhouse partner like Smoking Scholars is a watershed moment for our Company," said Lisa Nelson, President & CEO of CBD Life Sciences Inc. "This agreement validates our products on a national scale and gives us a strategic foothold in one of the most high-value markets in the country. For our shareholders, this deal represents not just immediate revenue but the beginning of long-term exponential growth."
Building Momentum from NECANN
CBDL's presence at NECANN continues to pay dividends. In addition to the Smoking Scholars partnership, management is actively engaged with multiple high-profile dispensaries across the Northeast, creating a robust pipeline of potential deals. The Company anticipates announcing additional agreements in the near future, further expanding its footprint and accelerating revenues.
Positioned for Long-Term Growth
With a diverse portfolio spanning pain management, relaxation, and skincare, CBDL is uniquely positioned to meet surging consumer demand for CBD and mushroom wellness products. Analysts forecast the global CBD market to grow at a CAGR of over 31% through 2030, with U.S. demand driving much of that expansion. By aligning with large-scale dispensary partners, CBDL is executing a strategy designed to capture substantial market share and deliver maximum shareholder value.
https://www.accessnewswire.com/newsroom/en/he...ow-1077348
With New York dispensaries projected to surpass $4.4 billion in annual sales by 2027, CBDL secures a transformative partnership poised to generate multi-million-dollar revenues and accelerate nationwide expansion.
SCOTTSDALE, AZ / ACCESS Newswire / September 30, 2025 / CBD Life Sciences Inc. (OTC:CBDL), through its operating subsidiary CBD Vault, today announced a game-changing client acquisition with Smoking Scholars, a premier dispensary located at 784 Allerton Ave in the Bronx, New York. This strategic agreement, finalized following CBDL's successful showcase at the NECANN New Jersey Conference, positions the Company to capture a powerful share of the booming New York cannabis and CBD marketplace.
Smoking Scholars is a multi-million-dollar enterprise with an elite client roster stretching across the United States. Their decision to bring CBD Vault into their packed product catalog is a resounding endorsement of CBDL's premium formulations and an entry point into one of the most competitive and rewarding markets in the nation.
Under the agreement, Smoking Scholars has placed a significant initial order featuring:
CBD Pain Relief Cream
CBD Massage Oil
Full Spectrum Gummies
CBD Infused Tea
Reishi Mushroom Face Cream
This order alone has the potential to generate hundreds of thousands in revenue within the next 12 months, with repeat orders expected as consumer demand for CBD wellness products accelerates. Importantly, this is just one of many dispensaries CBDL is securing as part of its rapid nationwide expansion.
Tapping Into One of America's Fastest-Growing Markets
New York's cannabis industry is undergoing explosive growth, with annual dispensary sales projected to exceed $4.4 billion by 2027. Consumer spending in the state is surging across both recreational and wellness categories, creating unparalleled opportunities for innovative brands like CBD Vault.
"Securing a powerhouse partner like Smoking Scholars is a watershed moment for our Company," said Lisa Nelson, President & CEO of CBD Life Sciences Inc. "This agreement validates our products on a national scale and gives us a strategic foothold in one of the most high-value markets in the country. For our shareholders, this deal represents not just immediate revenue but the beginning of long-term exponential growth."
Building Momentum from NECANN
CBDL's presence at NECANN continues to pay dividends. In addition to the Smoking Scholars partnership, management is actively engaged with multiple high-profile dispensaries across the Northeast, creating a robust pipeline of potential deals. The Company anticipates announcing additional agreements in the near future, further expanding its footprint and accelerating revenues.
Positioned for Long-Term Growth
With a diverse portfolio spanning pain management, relaxation, and skincare, CBDL is uniquely positioned to meet surging consumer demand for CBD and mushroom wellness products. Analysts forecast the global CBD market to grow at a CAGR of over 31% through 2030, with U.S. demand driving much of that expansion. By aligning with large-scale dispensary partners, CBDL is executing a strategy designed to capture substantial market share and deliver maximum shareholder value.
